top of page
Our
Mission
A heart transplant is often the only treatment for end-stage heart failure. Rather than giving patients a new heart through a transplant, we aim to do so by developing gene therapies for the treatment of cardiovascular disease. We currently focus on genetic cardiomyopathies characterized by aberrant mechanobiology, which we seek to treat by modulating mechanical force transduction.
Headquartered in Singapore, Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Nuevocor’s lead program is an adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. We plan to address additional currently untreatable autosomal dominant cardiomyopathies using our novel target discovery platform.
bottom of page